Does systemic-onset juvenile idiopathic arthritis belong under juvenile idiopathic arthritis?

Rheumatology

Volumn 44, Issue 11, 2005, Pages 1350-1353

  Ramanan, A V ^b,c   Grom, A A ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b ROYAL NATIONAL HOSPITAL FOR RHEUMATIC DISEASES   (United Kingdom)

^c SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

Hemophagocytic lymphohistiocytosis; Macrophage activation syndrome; Systemic onset JIA

Indexed keywords

ETANERCEPT; GAMMA INTERFERON; GOLD SALT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 6; MACROPHAGE MIGRATION INHIBITION FACTOR; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT ONSET STILL DISEASE; AUTOIMMUNE DISEASE ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; CELLULAR IMMUNITY; CHILD; CLINICAL FEATURE; CORRELATION FUNCTION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DNA POLYMORPHISM; GENETIC PREDISPOSITION; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HISTIOCYTIC LYMPHOMA; HUMAN; INCIDENCE; JUVENILE RHEUMATOID ARTHRITIS; LYMPHOCYTE FUNCTION; MACROPHAGE ACTIVATION SYNDROME; MAJOR HISTOCOMPATIBILITY COMPLEX; MORBIDITY; MORTALITY; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC DISEASE; SYSTEMIC ONSET JUVENILE RHEUMATOID ARTHRITIS; UNITED KINGDOM; VIRUS INFECTION;

ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CYTOKINES; HUMANS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MACROPHAGE ACTIVATION;

EID: 27744435759     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keh710     Document Type: Review

References (68)

1. Still GF. On a form of chronic joint disease in children. Med Chir Trans 1897;80:47-59.
2. Bywaters EG. George Frederic Still (1868-1941): His life and work. J Med Biogr 1994;2:125-31.
3. Schneider R, Laxer RM. Systemic onset juvenile rheumatoid arthritis. Baillieres Clin Rheumatol 1998;12:245-71.
4. Wallace CA, Levinson JE. Juvenile rheumatoid arthritis: Outcome and treatment for the 1990s. Rheum Dis Clin North Am 1991;17:891-905.
5. Schneider R, Laxer RM. Systemic-onset juvenile idiopathic arthritis. In: Isenberg DA, Maddison PJ, Woo P, Glass D, Breedveld FC, eds, Oxford Textbook of Rheumatology. Oxford: Oxford University Press, 2004:798-809.
6. Lindsley CB. Seasonal variation in systemic onset juvenile rheumatoid arthritis. Arthritis Rheum 1987;30:838-9.
7. Feldman BM, Birdi N, Boone JE et al. Seasonal onset of systemic-onset juvenile rheumatoid arthritis. J Pediatr 1996;129:513-18.
8. Oen K, Fast M, Postl B. Epidemiology of juvenile rheumatoid arthritis in Manitoba, Canada, 1975-92: Cycles in incidence. J Rheumatol 1995;22:745-50.
9. Uziel Y, Pomeranz A, Brik R et al. Seasonal variation in systemic onset juvenile rheumatoid arthritis in Israel. J Rheumatol 1999;26:1187-9.
10. Lomater C, Gerloni V, Gattinara M, Mazzotti J, Cimaz R, Fantini F. Systemic onset juvenile idiopathic arthritis: A retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol 2000; 27:491-6.
11. Lang BA, Schneider R, Reilly BJ, Silverman ED, Laxer RM. Radiologic features of systemic onset juvenile rheumatoid arthritis. J Rheumatol 1995;22:168-73.
12. Nepom BG, Glass DN. Juvenile rheumatoid arthritis and HLA: Report of the Park City III workshop. J Rheumatol 1992; 33(Suppl):70-4.
13. Thompson SD, Moroldo MB, Guyer L et al. A genome-wide scan for juvenile rheumatoid arthritis in affected sibpair families provides evidence of linkage. Arthritis Rheum 2004;50:2920-30.
14. Date Y, Seki N, Kamizono S et al. Identification of a genetic risk factor for systemic juvenile rheumatoid arthritis in the 5′-flanking region of the TNFalpha gene and HLA genes. Arthritis Rheum 1999; 42:2577-82.
15. Fishman D, Faulds G, Jeffery R et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998;102:1369-76.
16. Ogilvie EM, Fife MS, Thompson SD et al. The -174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: A multicenter study using simplex and multiplex juvenile idiopathic arthritis families. Arthritis Rheum 2003;48:3202-6.
17. Donn RP, Shelley E, Ollier WE, Thomson W, British Paediatric Rheumatology Study Group. A novel 5′-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2001; 44:1782-5.
18. De Benedetti F, Meazza C, Vivarelli M et al. Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2003;48:1398-407.
19. Keul R, Heinrich PC, Muller-Newen G, Muller K, Woo P. A possible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis. Cytokine 1998;10:729-34.
20. Rooney M, David J, Symons J, Di Giovine F, Varsani H, Woo P. Inflammatory cytokine responses in juvenile chronic arthritis. Br J Rheumatol 1995;34:454-60.
21. Pignatti P, Vivarelli M, Meazza C, Rizzolo MG, Martini A, De Benedetti F. Abnormal regulation of interleukin 6 in systemic juvenile idiopathic arthritis. J Rheumatol 2001;28:1670-6.
22. Muzaffer MA, Dayer JM, Feldman BM et al. Differences in the profiles of circulating levels of soluble tumor necrosis factor receptors and interleukin 1 receptor antagonist reflect the heterogeneity of the subgroups of juvenile rheumatoid arthritis. J Rheumatol 2002; 29:1071-8.
23. Mangge H, Kenzian H, Gallistl S et al. Serum cytokines in juvenile rheumatoid arthritis. Correlation with conventional inflammation parameters and clinical subtypes. Arthritis Rheum 1995;38:211-20.
24. Quartier P, Taupin P, Bourdeaut F et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003;48:1093-101.
25. Kimura YP, Higgins G. Treatment of systemic JIA with etanercept: A follow-up study. Arthritis Rheum 2002;46:S481.
26. De Benedetti F, Martini A. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol 1998;25:203-7.
27. Prieur AM, Roux-Lombard P, Dayer JM. Dynamics of fever and the cytokine network in systemic juvenile arthritis. Rev Rhum Engl Ed 1996;63:163-70.
28. Yokota SM, Imagawa T. Phase II trial of anti-IL-6 receptor antibody (MRA) for children with systemic onset juvenile idiopathic arthritis. Arthritis Rheum 2003;48:S429.
29. Verbsky JW, White AJ. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 2004;31:2071-5.
30. Irigoyen PI, Olsen J, Hom C, Ilowite NT. Treatment of systemic onset juvenile rheumatoid arthritis with anakinra. Arthritis Rheum 2004;50:S437.
31. Henricksen M. Efficacy of anakinra in refractory systemic arthritis. Arthritis Rheum 2004;50:S438.
32. Prieur AM, Kaufmann MT, Griscelli C, Dayer JM. Specific interleukin-1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis. Lancet 1987;2:1240-2.
33. Couzin J. Basic and clinical immunology meeting. And action! Dendritic cells go live. Science 2004;305:772-3.
34. Ramanan AV, Schneider R. Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol 2003;30:401-3.
35. Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: A potentially fatal complication of rheumatic disorders. Arch Dis Child 2001;85:421-6.
36. Stephan JL, Kone-Paut I, Galambrun C, Mouy R, Bader-Meunier B, Prieur AM. Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology 2001;40:1285-92.
37. Davies SV, Dean JD, Wardrop CA et al. Epstein-Barr virus-associated haemophagocytic syndrome in a patient with juvenile chronic arthritis. Br J Rheumatol 1994;33:495-7.
38. Cuende E, Vesga JC, Perez LB, Ardanaz MT, Guinea J. Macrophage activation syndrome as the initial manifestation of systemic onset juvenile idiopathic arthritis. Clin Exp Rheumatol 2001;19:764-5.
39. Prahalad S, Bove KE, Dickens D, Lovell DJ, Grom AA. Etanercept in the treatment of macrophage activation syndrome. J Rheumatol 2001;28:2120-4.
40. Bloom BJ, Tucker LB, Miller LC, Schaller JG. Fibrin D-dimer as a marker of disease activity in systemic onset juvenile rheumatoid arthritis. J Rheumatol 1998;25:1620-5.
41. Athreya BH. Is macrophage activation syndrome a new entity? Clin Exp Rheumatol 2002;20:121-3.
42. Ramanan AV, Schneider R. Macrophage activation syndrome - what's in a name! J Rheumatol 2003;30:2513-16.
43. Emmenegger U, Reimers A, Frey U et al. Reactive macrophage activation syndrome: A simple screening strategy and its potential in early treatment initiation. Swiss Med Wkly 2002;132:230-6.
44. Favara BE, Feller AC, Pauli M et al. Contemporary classification of histiocytic disorders. The WHO Committee on Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol 1997;29:157-66.
45. Goransdotter Ericson K, Fadeel B, Nilsson-Ardnor S et al. Spectrum of perform gene mutations in familial hemophagocytic lymphohistiocytosis. Am J Hum Genet 2001;68:590-7.
46. Janka G, Imashuku S, Elinder G, Schneider M, Henter J-I. Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am 1998;12:435-44.
47. Egeler RM, Shapiro R, Loechelt B, Filipovich A. Characteristic immune abnormalities in hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol 1996;18:340-5.
48. Sullivan KE, Delaat CA, Douglas SD, Filipovich AH. Defective natural killer cell function in patients with hemophagocytic lymphohistiocytosis and in first degree relatives. Pediatr Res 1998;44:465-8.
49. Neeft M, Wieffer M, de Jong AS et al. Munc13-4 is an effector of rab27a and controls secretion of lysosomes in hematopoietic cells. Mol Biol Cell 2005;16:731-41.
50. Feldmann J, Callebaut I, Raposo G et al. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell 2003;115:461-73.
51. Feldmann J, Le Deist F, Fischer A, de Saint Basile G. [Munc13-4 is essential for cytolytic granule fusion]. Med Sci (Paris) 2004;20:144-6.
52. Grom AA, Villanueva J, Lee S, Goldmuntz EA, Passo MH, Filipovich A. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr 2003;142:292-6.
53. Wulffraat NM, Rijkers GT, Elst E, Brooimans R, Kuis W. Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation. Rheumatology 2003;42:375-9.
54. Villanueva J, Lee S, Giannini EH et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther 2005;7:10.
55. Arnaout RA. Perform deficiency: Fighting unarmed? Immunol Today 2000;21:592 (author reply 593-4).
56. Arico M, Danesino C, Pende D, Moretta L. Pathogenesis of haemophagocytic lymphohistiocytosis. Br J Haematol 2001; 114:761-9.
57. Kagi D, Odermatt B, Mak TW. Homeostatic regulation of CD8+ T cells by perforin. Eur J Immunol 1999;9:3262-72.
58. Stepp SE, Mathew PA, Bennett M, de Saint Basile G, Kumar V. Perforin: more than just an effector molecule. Immunol Today 2000;21:254-6.
59. Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood 2004;104:735-43.
60. Ramanan AV, Wynn RF, Kelsey A, Baildam EM. Systemic juvenile idiopathic arthritis, Kikuchi's disease and haemophagocytic lymphohistiocytosis - is there a link? Case report and literature review. Rheumatology 2003;42:596-8.
61. Ohta A, Matsumoto Y, Ohta T, Kaneoka H, Yamaguchi M. Still's disease associated with necrotizing lymphadenitis (Kikuchi's disease): Report of 3 cases. J Rheumatol 1988;15:981-3.
62. Oliveira S, Destri UBW, Vasquez LCO, Ferman S, Romano S, Sztajnbok FR. Systemic juvenile idiopathic arthritis associated with Kikuchi's disease. Ann Rheum Dis 2000;59(Suppl):731.
63. Cousin F, Grezard P, Roth B, Balme B, Gregoire-Bardel M, Perrot H. Kikuchi disease associated with Still disease. Int J Dermatol 1999; 38:464-7.
64. Wong KF, Hui PK, Chan JK et al. The acute lupus hemophagocytic syndrome. Ann Intern Med 1991;114:387-90.
65. Breit W, Frosch M, Meyer U, Heinecke A, Ganser G. A subgroup-specific evaluation of the efficacy of intraarticular triamcinolone hexacetonide in juvenile chronic arthritis. J Rheumatol 2000; 27:2696-702.
66. Halle F, Prieur AM. Evaluation of methotrexate in the treatment of juvenile chronic arthritis according to the subtype. Clin Exp Rheumatol 1991;9:297-302.
67. Speckmaier M, Findeisen J, Woo P et al. Low-dose methotrexate in systemic onset juvenile chronic arthritis. Clin Exp Rheumatol 1989; 7:647-50.
68. Woo P, Southwood TR, Prieur AM et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2000;43:1849-57.